Spots Global Cancer Trial Database for A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer
Official Title: A Dose-escalation Study of the Safety and Pharmacology of DAN-222 in Subjects With Metastatic Breast Cancer
Study ID: NCT05261269
Conditions
Study Description
Brief Summary: This was an open-label, multicenter, dose-escalation study designed to assess the safety, tolerability, and PK of IV administered DAN-222 followed by a dose-escalation of DAN-222 in combination with niraparib: * Part A is dose escalation of single agent DAN-222 * Part B is dose escalation of DAN-222 in combination with niraparib
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
UC San Diego Moores Cancer Center, La Jolla, California, United States
UCLA - Parkside Cancer Center, Santa Monica, California, United States
H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
University of Michigan, Ann Arbor, Michigan, United States
Saint Luke's Cancer Institute, Jackson, Missouri, United States
Icahn School of Medicine at Mount Sinai, New York, New York, United States
The University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
Magee Women's Hospital, Pittsburgh, Pennsylvania, United States
Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
